High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer

Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer

(2015) Nathaniel Melling et al.   HISTOPATHOLOGY

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

(2015) Chiara Cremolini et al.   LANCET ONCOLOGY

Tissue-based map of the human proteome

(2015) M. Uhlen et al.   SCIENCE

Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer

(2015) Sven-Erik Olofsson et al.   PLoS One

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort

(2015) Halfdan Sorbye et al.   PLoS One

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer

(2013) Karolina Boman et al.   BMC Urology

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

(2011) T Yokota et al.   BRITISH JOURNAL OF CANCER

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study

(2011) Liv Jonsson et al.   Journal of Translational Medicine

High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer

(2011) Barbara Hjelm et al.   Proteomics Clinical Applications

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer

(2010) Åsa Ehlén et al.   Journal of Translational Medicine

A new generation of proto-oncogenes: Cold-inducible RNA binding proteins

(2009) M.E. LLeonart   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients

(2009) Halfdan Sorbye et al.   CANCER

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer

(2009) Annika Jögi et al.   MODERN PATHOLOGY

The RNA-Binding Protein RBM3 Is Required for Cell Proliferation and Protects Against Serum Deprivation-Induced Cell Death

(2009) Sven Wellmann et al.   PEDIATRIC RESEARCH